A retinoid may also be used in conjunction with one of the combination products described above ... is approved for the treatment of acne vulgaris (and rosacea). Both nicotinamide and zinc ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received approval from the MHRA for marketing Winlevi, an acne treatment, in the UK. The product, which targets patients aged 12 and older, ...

Cosmo CEO Giovanni Di Napoli said the milestone underscores the company's commitment, alongside Glenmark, to provide patients ...

Glenmark Pharmaceuticals receives UK approval for Winlevi, a groundbreaking topical acne treatment with unique mechanism of ...

Glenmark Pharmaceuticals Ltd, in collaboration with Cosmo Pharmaceuticals N.V., has received approval from the UK Medicines ...

Laser therapy for acne vulgaris is a safe and effective option as both an alternative or adjunctive therapy across skin types.

A new study published in the Journal of Drugs in Dermatology showed that adults with acne responded well to a regimen that ...

Dublin, Ireland and Mumbai, India and London, United Kingdom--( - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a ...

Cosmo Pharmaceuticals N.V. (and Glenmark Pharmaceuticals (Glenmark) announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi ...

Glenmark Pharmaceuticals and Cosmo Pharmaceuticals have received MHRA approval for Winlevi, a topical treatment for acne vulgaris in the UK. This partnership expands Glenmark's dermatology portfolio.

Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global ...